Li Wang

Stories

Novartis licenses Abogen's mRNA T-cell engager in up to $7.8 billion deal

As of October 2026: Presented first-in-human data for ABO2203 at AACR 2026

Novartis agreed to pay up to $7.8 billion for rights to Chinese biotech Abogen's mRNA therapeutics. The deal includes a $575 million upfront payment and an exclusive worldwide license to ABO2203, the first mRNA-encoded T-cell engager to reach clinical testing in autoimmune disease.

Updated Oct 2